Chaim Bernstein, MD
Pulmonary Disease · Brooklyn, NYNPI 1548262348
Payments from drug & device makers
Across 886 payments — averaging $209.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$74K
- Mallinckrodt Hospital Products Inc.$44K
- Sunovion Pharmaceuticals Inc.$21K
- Insmed, Inc.$14K
- Verona Pharma, Inc.$9K
- Mallinckrodt Enterprises LLC$7K
- plus $16K from 22 others
What the payments were for
- Consulting fees$14,8168%
- Speaking & faculty fees$141,80276%
- Travel & lodging$5,0923%
- Food & beverage$23,37213%
- Education$8260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 185 | $74,478 |
| Mallinckrodt Hospital Products Inc. | 59 | $44,456 |
| Sunovion Pharmaceuticals Inc. | 58 | $20,579 |
| Insmed, Inc. | 70 | $13,618 |
| Verona Pharma, Inc. | 28 | $9,435 |
| Mallinckrodt Enterprises LLC | 7 | $7,316 |
| GSK | 76 | $4,505 |
| AstraZeneca | 120 | $3,458 |
| Baxter Healthcare | 51 | $2,043 |
| Philips North America LLC | 79 | $1,751 |
| Advanced Respiratory, Inc | 33 | $1,136 |
| Mylan Specialty L.p. | 30 | $587 |
| Medtronic | 4 | $541 |
| Regeneron Healthcare Solutions, Inc. | 15 | $517 |
| Sanofi | 20 | $481 |
| Amgen | 12 | $251 |
| Electromed, Inc. | 15 | $218 |
| Actelion Pharmaceuticals US, Inc. | 6 | $179 |
| Viatris Specialty LLC | 4 | $104 |
| Teva Pharmaceuticals USA, Inc. | 4 | $94 |
| Genentech USA, Inc. | 2 | $39 |
| United Therapeutics Corporation | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Novo Nordisk | 1 | $16 |
| Merck | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| 3b Medical, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$54,523
- ACTHAR$50,855
- LONHALA MAGNAIR$20,012
- Ohtuvayre$9,184
- Arikayce$9,148
- FASENRA$1,192
- TEZSPIRE$1,040
- BREZTRI$915
- Hillrom - Vest System Model 105 Home Care$551
- AIRSUPRA$546
- NUCALA$517
- ENDURANT IIS$355
- DUPIXENT$250
- inCourage$213
- FARXIGA$161
- SYMBICORT$153
- Valiant Captivia$138
- Life 2000 Ventilation System$120
- The Monarch Airway Clearance System$106
How this compares
$185,908 in reported general payments places this provider in the 90th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 32 | $341,508 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 76 | $81,954 |
| Fasenra PenBenralizumab | 13 | $73,622 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $66,972 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 100 | $47,587 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $22,910 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 22 | $13,445 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $12,242 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 57 | $9,848 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $7,238 |
| BreynaBudesonide/Formoterol Fumarate | 26 | $5,826 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 98 | $3,318 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $2,340 |
| Ipratropium Bromide | 26 | $994 |
| Nifedipine ErNifedipine | 19 | $733 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat | $74,478 | $354,95354 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $3,458 | $136,779196 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $4,505 | $102,123119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Brooklyn
- Ali El AtatBrooklyn$547K
- Sunil MehraBrooklyn$388K
- Aaliya BurzaBrooklyn$334K
- Xiaojun YanBrooklyn$249K
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.